Date: 2013-09-03
Type of information: Commercialisation agreement
Compound: immortalized target cells for the characterization of biosimilars
Company: Evercyte (Austria) Vela Labs (Austria)
Therapeutic area: Technology - Services
Type agreement: commercialisation
Action mechanism:
Disease:
Details: * On September 3, 2013, VelaLabs, a provider of analytical services to the global biopharmaceutical industry, and Evercyte, a producer of standardized, relevant cell systems, have entered into a cooperation to commercialize immortalized target cells for the characterization of biosimilars in a GMP environment. Combining Vela’s long-standing expertise in the characterization of biosimilars with Evercyte’s know-how to immortalize relevant primary target cells, the partnership will provide product-tailored bioassays. A VEGF-responsive cell line (HUVEC) has already been established for potency testing of bevacizumab (Avastin®) biosimilars.
GMP certified VelaLabs provides a broad portfolio of analytical methods for the preclinical and clinical development including studies in support of regulatory submissions and product release of biopharmaceuticals and biosimilars, including monoclonal antibodies and growth factors. Evercyte offers immortalized cells that retain their primary-like human cell characteristics for pharmaceutical R&D. Recently Evercyte entered the market for induced pluripotent stem cells by establishing human urine as a fully non-invasive method to generate relevant cellular model systems. Systematically establishing and commercializing relevant cell model systems from donors of different genetic backgrounds as “pharmacocellomics™” will also improve the predictability of substance efficiencies and side effects in the general population. Evercyte is a spin-off company of the University of Natural Resources and Life Sciences Vienna (BOKU-VIBT), Austria.
Financial terms:
Latest news:
